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Preclinical molecular imaging has become an essential tool
in translating the scienti c understanding that has been
gained by studying and developing the animal models of
multiple human diseases to the clinic [1]. Today, several of
the current clinical imaging techniques are already available
for use in preclinical imaging models. It has allowed that
same parameters can be derived from preclinical and clinical
images, which has meant a swift translational trajectory for
many clinical trials in oncology [2], neurology [3] or in-
ammation [4], or cardiology [5]. ese parameters can be
considered as imaging biomarkers because they represent
objective physical and biological characteristics of tissues,
tumours, or organs, and they can help to identify normal or
pathogenic processes and treatment response. Nevertheless,
the use of preclinical molecular imaging is still limited due to
the lack of ecient and standardized methods for extracting
accurate and reproducible imaging biomarkers for each
particular disease model. e translational bene t of pre-
clinical molecular imaging will substantially increase by
improving the reliability of the collected data [6]. In this
regard, a key challenge in translational molecular imaging is
to de ne appropriate imaging biomarkers for each disease
for prediction of therapeutic outcome and follow-up of new
treatments. is will help in swift and successful translation
of studies from small animal models to patients and con-
sequently reduce the cost of drug discovery portfolio. is
special issue focuses on the recent advances in quantitative
imaging biomarkers that can be used for translational re-
search. In particular, it promotes the discussion of the
various methods that bene t from the use of markers derived
from preclinical imaging techniques that can be directly
transferred to clinical imaging.
is special issue contains both review (2) and original
articles (8), and its focus is to provide insights into the
methodologies to investigate new imaging biomarkers in
translational small animal models. An open call for papers
was announced in December 2017, and the submission
deadline was in August 2018. In total, 20 articles were
submitted, and 10 articles were accepted for publication. In
terms of imaging modality, all articles used magnetic res-
onance imaging (MRI) (7 articles) and/or positron emission
tomography (PET) (7 articles), of which 3 articles utilised
both MRI and PET. Only one of the review articles included
other imaging techniques, but even in that case, PET and
MRI were the predominant imaging techniques. erefore,
it seems that both PETandMRI are ecient research tools in
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the domain of translational preclinical imaging. In terms of
disease animal models, the clinical conditions were mainly
oncology (brain, breast, and pancreatic cancer) and car-
diovascular diseases (cardiovascular dysfunction and ath-
erosclerosis) and other clinical ﬁelds such as radiotherapy
(neutron capture and high energy photons). Obviously, the
articles included in this special issue represent only a small
part of the uses of translational molecular imaging in animal
models, but we believe that they can be representative in
relative terms. #e predominance of PET and MRI could be
interpreted as the consequence of their higher translational
potential if compared with optical imaging or ultrasound.
In brief, the published papers on oncology show bio-
markers for monitoring therapies such as radiation treat-
ment and its side eﬀects. S. De Bruycker et al. reviewed the
diﬀerent approaches to generate hypoxic in vivo cancer
models directly related to PET imaging. N. Kova´cs et al. in
their original paper performed a study to monitor the dose-
limiting organs in patients undergoing radiotherapy. #ey
report that conventional SUV values derived from brain PET
and apparent diﬀusion coeﬃcients from DWI can be con-
sidered as biomarkers for the follow-up of the health status
after radiation therapy.
Among the other research articles, some were focused on
new tracers and contrast agents. A. Leftin and J. A. Koutcher
showed that tumour-associated macrophages can be accu-
rately estimated in a mouse model of breast cancer by fo-
cusing on spatial distributions of iron deposits rather than
ROI averages. #ey found that the polarization status of the
iron+ populations is aﬀected by contrast-agent injection,
which has broad implications for nanoparticle-enhanced
biomedical imaging. #e paper by K.-H. Jung et al. was
focused on the use of new agents for theragnostic approaches
based on MRI and neutron capture therapies, showing in-
creased MRI signal in the tumour after therapy. Also, new
radiolabelled peptides and antibodies were proposed by M.
A. Morcillo et al. as novel PET biomarkers for the diagnosis
and prognosis of pancreatic ductal adenocarcinoma. Finally,
J. Buck et al. described a novel arterial spin labelling MRI
method to perform accurate and robust measurements of
cerebral blood ﬂow.
In metabolism and cardiology, diﬀerent PET and MRI
biomarkers were proposed by Y. H. Chung et al. for mea-
suring the myocardial glucose adaptations in high-fat-diet-
induced insulin resistance, and novel PET tracers were
proposed by S. Hellberg et al. to improve characteristics for
imaging atherosclerotic plaque inﬂammation. In neurology,
R. Gandhi et al. reported in their systematic review diﬀerent
uses of preclinical imaging techniques of postischaemia
neurovascular remodeling. Finally, a technical research ar-
ticle by D. Deidda et al. proposes a novel PET image re-
construction algorithm by utilizing MRI information. #is
approach oﬀers the opportunity to extract the time-activity
curve from the images so that kinetic information can be
calculated without the potential need of continuous arterial
blood sampling from animals. All ten articles illustrate that
the value of predominantly PET and MRI biomarkers in
diﬀerent animal models oﬀers useful biological information
in various clinical applications. It is interesting to note that
hybrid PET/MRI imaging was performed only in the
technical article, whereas in the others, only PETor MRI was
used. #us, it remains to be seen if this powerful machine
can become a mainstream multimodality imaging tool to
oﬀer substantially improved information than standalone
PET and MRI [7].
We envision the scientiﬁc ﬁndings and knowledge
printed in this special issue demonstrate the importance of
PET and MRI imaging biomarkers in preclinical in-
vestigations as well as the need for standardisation of the
imaging biomarkers of each particular disease model and for
the follow-up of new treatments and drugs from the small
animal model to the patient.
Finally, we would like to thank the reviewers for their
valuable review comments, improving greatly the quality of
all submitted papers.
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